Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
"the gene therapy company announced a license option agreement with Pfizer Inc. PFE, -0.24% that could valued at more than $600 million. Trading volume spiked up to 3.9 million shares ahead of the open, which compares with the full-day average of about 173,000 shares. The agreement allows Pfizer to exercise options to license novel capsids generated from Voyager's RNA-driven screener technology, which would be used by Pfizer to develop, make and commercialize gene therapies. As part of the agreement, Voyager will receive an upfront payment of $30 million, and is entitled to receive up to $20 million in exercise fees. Voyager will also be eligible to receive up to $580 million in milestone payments, and will be eligible to receive "mid- to high-single-digit tiered royalties" based on sales of Pfizer products using the licensed capsids."
"the gene therapy company announced a license option agreement with Pfizer Inc. PFE, -0.24% that could valued at more than $600 million. Trading volume spiked up to 3.9 million shares ahead of the open, which compares with the full-day average of about 173,000 shares. The agreement allows Pfizer to exercise options to license novel capsids generated from Voyager's RNA-driven screener technology, which would be used by Pfizer to develop, make and commercialize gene therapies. As part of the agreement, Voyager will receive an upfront payment of $30 million, and is entitled to receive up to $20 million in exercise fees. Voyager will also be eligible to receive up to $580 million in milestone payments, and will be eligible to receive "mid- to high-single-digit tiered royalties" based on sales of Pfizer products using the licensed capsids."
“The fact is that if traders really believed that anything could happen at any time, there would be considerably fewer losers and more consistent winners.”
― Mark Douglas, Trading in the Zone
― Mark Douglas, Trading in the Zone